When initiating ribociclib (Kisqali), what ECG (electrocardiogram) monitoring protocol should be followed?

ECG Monitoring Protocol for Kisqali (Ribociclib)

When initiating Kisqali (ribociclib), obtain a baseline ECG before starting treatment, repeat at approximately Day 14 of the first cycle, and monitor electrolytes at the beginning of each cycle for the first 6 cycles. 1

Baseline Assessment (Before Starting Kisqali)

• Obtain baseline ECG to measure QTc interval 1
• Check electrolytes (potassium and magnesium) and correct any abnormalities before initiating treatment 1
• Avoid starting Kisqali if baseline QTc is significantly prolonged or if patient has long QT syndrome 1

Early Treatment Monitoring

Day 14 of Cycle 1 is the critical timepoint when QTc prolongation peaks with ribociclib:

• Repeat ECG at approximately Day 14 of the first cycle 1
• This timing captures the maximal QT effect, as studies show QTc peaks around day 14 (mean increase of 16 ms) before decreasing by day 28 2, 3

Ongoing Monitoring Protocol

Electrolyte monitoring:

• Check potassium and magnesium at the beginning of each cycle for the first 6 cycles 1
• Continue monitoring as clinically indicated thereafter 1

ECG monitoring:

• Repeat ECGs as clinically indicated after the Day 14 assessment 1
• Obtain ECG after any dose adjustments 1
• More frequent monitoring if QTc prolongation develops or if using concomitant QT-prolonging drugs 1

Management of QTc Prolongation

The evidence shows ribociclib has the strongest signal for QT prolongation among CDK4/6 inhibitors 4, requiring vigilant monitoring:

• If QTc >480 ms or increase >60 ms from baseline: Hold Kisqali, correct electrolytes, and do not resume until QTc normalizes 1
• Grade 3-4 QTc prolongation: Requires dose reduction or permanent discontinuation depending on recurrence 1

Key Caveats

• Avoid concomitant use with other QT-prolonging drugs (especially tamoxifen, which is specifically contraindicated with ribociclib) 1
• Avoid strong CYP3A inhibitors as they significantly increase ribociclib levels and QT prolongation risk 1
• The 400 mg dose used in early breast cancer has lower QTc prolongation risk (mean 10 ms increase) compared to the 600 mg dose used in advanced disease (mean 20-24 ms increase) 5, 3
• Most adverse events, including QT prolongation, occur within the first month of treatment, with lowest incidence between months 2-6, then rising again after 6 months 4